NASDAQ:SPRB Spruce Biosciences (SPRB) Stock Price, News & Analysis $0.55 +0.02 (+3.79%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Spruce Biosciences Stock (NASDAQ:SPRB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Spruce Biosciences alerts:Sign Up Key Stats Today's Range$0.53▼$0.5650-Day Range$0.43▼$0.5952-Week Range$0.41▼$5.95Volume325,144 shsAverage Volume493,534 shsMarket Capitalization$22.64 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingHold Company OverviewSpruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Read More… Sell NVDA Now? (Ad)Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Spruce Biosciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks60th Percentile Overall ScoreSPRB MarketRank™: Spruce Biosciences scored higher than 60% of companies evaluated by MarketBeat, and ranked 401st out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingSpruce Biosciences has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageSpruce Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Spruce Biosciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Spruce Biosciences are expected to grow in the coming year, from ($1.12) to ($1.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spruce Biosciences is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spruce Biosciences is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpruce Biosciences has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Spruce Biosciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.69% of the outstanding shares of Spruce Biosciences have been sold short.Short Interest Ratio / Days to CoverSpruce Biosciences has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Spruce Biosciences has recently decreased by 20.76%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSpruce Biosciences does not currently pay a dividend.Dividend GrowthSpruce Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.69% of the outstanding shares of Spruce Biosciences have been sold short.Short Interest Ratio / Days to CoverSpruce Biosciences has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Spruce Biosciences has recently decreased by 20.76%, indicating that investor sentiment is improving significantly. News and Social Media0.9 / 5News Sentiment-0.32 News SentimentSpruce Biosciences has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Spruce Biosciences this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for SPRB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Spruce Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.10% of the stock of Spruce Biosciences is held by insiders.Percentage Held by Institutions91.71% of the stock of Spruce Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Spruce Biosciences' insider trading history. Receive SPRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address SPRB Stock News HeadlinesSpruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Reach OutNovember 1 at 5:32 PM | stockhouse.comSpruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation ConferenceOctober 28, 2024 | businesswire.comSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.November 2, 2024 | Chaikin Analytics (Ad)Spruce Biosciences (NASDAQ:SPRB) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comAnalysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Spruce Biosciences (SPRB)September 12, 2024 | markets.businessinsider.comThe Schall Law Firm Is Looking Into Whether Spruce Biosciences, Inc. Committed Securities Fraud And The Firm Wants Affected Shareholders To Reach OutSeptember 10, 2024 | stockhouse.comSpruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | finance.yahoo.comThe Schall Law Firm Is Investigating Spruce Biosciences Inc For Potential Securities Law Violations And Investors Are Urged To Reach OutAugust 25, 2024 | stockhouse.comSee More Headlines SPRB Stock Analysis - Frequently Asked Questions How have SPRB shares performed this year? Spruce Biosciences' stock was trading at $2.93 at the beginning of the year. Since then, SPRB stock has decreased by 81.3% and is now trading at $0.5482. View the best growth stocks for 2024 here. How were Spruce Biosciences' earnings last quarter? Spruce Biosciences, Inc. (NASDAQ:SPRB) posted its earnings results on Monday, August, 12th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.32) by $0.10. The business earned $1.61 million during the quarter, compared to the consensus estimate of $1.55 million. Spruce Biosciences had a negative trailing twelve-month return on equity of 59.94% and a negative net margin of 450.38%. When did Spruce Biosciences IPO? Spruce Biosciences (SPRB) raised $75 million in an initial public offering on Friday, October 9th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets acted as the underwriters for the IPO. How do I buy shares of Spruce Biosciences? Shares of SPRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Spruce Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Spruce Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), Adobe (ADBE), Meta Platforms (META) and Disc Medicine (IRON). Company Calendar Last Earnings8/12/2024Today11/02/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SPRB CUSIPN/A CIK1683553 Webwww.sprucebiosciences.com Phone415-655-4168FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$10.00 Low Stock Price Target$2.00 Potential Upside/Downside+812.1%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,920,000.00 Net Margins-450.38% Pretax Margin-450.38% Return on Equity-59.94% Return on Assets-45.38% Debt Debt-to-Equity Ratio0.02 Current Ratio5.17 Quick Ratio5.17 Sales & Book Value Annual Sales$10.09 million Price / Sales2.24 Cash FlowN/A Price / Cash FlowN/A Book Value$1.88 per share Price / Book0.29Miscellaneous Outstanding Shares41,300,000Free Float37,544,000Market Cap$22.64 million OptionableOptionable Beta2.40 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:SPRB) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spruce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.